Literature DB >> 3890132

Carnitine and left ventricular function in haemodialysis patients.

B Fagher, G Cederblad, M Monti, L Olsson, B Rasmussen, H Thysell.   

Abstract

Left ventricular function was non-invasively studied in 28 randomly selected haemodialysis patients before and after administration of L-carnitine, 2 g i.v. three times per week or saline in a double blind designed study over a six-week period. Cardiac function variables showed no relationship to muscle (vastus lateralis) and plasma carnitine concentrations. No apparent deficiency in muscle carnitine was found, whereas total plasma carnitine was lower in female patients than in female controls, p less than 0.002. The echocardiographic left ventricular end-diastolic diameter was initially increased in about one third and the ejection fraction was depressed in about one fifth of the patients. An increased A:H ratio was found in 15%. Systolic time intervals were deranged in 30% of the patients. After carnitine administration, marked increases of muscle and plasma carnitine levels were found, p less than 0.01, but no effects were recorded in any of the cardiac tests. Muscle carnitine increased from 14.6 mmol/kg dry weight to a median of 23.7 mmol/kg. We found no support for the hypothesis that carnitine depletion is responsible for cardiac dysfunction in haemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890132     DOI: 10.3109/00365518509160995

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

2.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

3.  Hemodynamic stabilizing effects of L-carnitine in chronic hemodialysis patients.

Authors:  Y Kudoh; S Aoyama; T Torii; Q Chen; D Nagahara; H Sakata; A Nozawa
Journal:  Cardiorenal Med       Date:  2013-09-27       Impact factor: 2.041

4.  Carnitine supplementation improves cardiac strain rate in children on chronic hemodialysis.

Authors:  Kristen Sgambat; Lowell Frank; Ahmad Ellini; Craig Sable; Asha Moudgil
Journal:  Pediatr Nephrol       Date:  2012-03-22       Impact factor: 3.714

Review 5.  Cardiac metabolic remodelling in chronic kidney disease.

Authors:  Nikayla Patel; Muhammad Magdi Yaqoob; Dunja Aksentijevic
Journal:  Nat Rev Nephrol       Date:  2022-05-30       Impact factor: 42.439

6.  The effect of levocarnitine supplementation on dialysis-related hypotension: A systematic review, meta-analysis, and trial sequential analysis.

Authors:  Api Chewcharat; Pol Chewcharat; Weitao Liu; Jacqueline Cellini; Elizabeth A Phipps; Jill A Melendez Young; Sagar U Nigwekar
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

Review 7.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.